サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451122

静注（IV）液市場レポート：タイプ別、栄養別、地域別、2024-2032

Intravenous Solutions Market Report by Type (Partial Parenteral Nutrition, Total Parenteral Nutrition), Nutrients (Carbohydrates, Salts and Electrolytes, Minerals, Vitamins, Amino Acids), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 141 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.33円
静注（IV）液市場レポート：タイプ別、栄養別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の静注（IV）液市場規模は2023年に148億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに232億米ドルに達し、2024年から2032年の間に4.9%の成長率（CAGR）を示すと予測しています。慢性疾患の蔓延、老人人口の増加、急速な技術進歩、ヘルスケア施設の拡大、政府や規制機関による支援政策の発動、在宅医療へのシフトの高まりなどが、市場を推進する主な要因となっています。

静注（IV）液とは、患者の血流に直接輸液するための無菌液体を指します。等張液、高張液、低張液があり、さまざまな医療ニーズに対応しています。水、電解質、糖、ビタミン、薬剤など、さまざまな成分を用いて製造されます。静注（IV）液は、水分補給療法、栄養補給、薬物投与、輸血、化学療法、疼痛管理、電解質不均衡の是正、解毒治療などに広く使用されています。管理された投与、消化器系への影響の軽減、オーダーメイドの栄養供給、血流への直接アクセス、回復支援の強化など、いくつかの利点があります。

病院、診療所、専門医療センターなどのヘルスケア施設の急速な拡大により、静脈内治療の機会が増えていることが、市場の成長を後押ししています。さらに、ヘルスケア施設全体で高品質の静注（IV）液を利用できるようにするため、政府や規制機関が支援政策を打ち出していることも、市場成長にプラスの影響を与えています。さらに、緊急場面や外科手術における静脈注射液の需要の高まりが、市場の成長に寄与しています。これとは別に、患者が自宅で治療を受ける在宅ヘルスケアへのシフトが進んでいることも、特殊な静注（IV）液の需要を促進しています。これに加えて、パンデミックなどの世界の健康上の緊急事態において、多数の患者を迅速に治療するための製品用途が増加していることが、市場の成長を促進しています。

静注（IV）液市場の動向と促進要因：

疾病の有病率の増加

糖尿病、心血管疾患、がん、急性疾患など、静脈内治療を必要とする慢性疾患の有病率の増加は、市場成長を促進する顕著な要因です。さらに、慢性疾患の増加につながるライフスタイルの変化、環境要因、遺伝的素因などの新たな世界の動向が、もう一つの成長促進要因として作用しています。さらに、いくつかの慢性疾患や急性疾患では、静注（IV）液、栄養剤、薬剤を血流に直接投与する必要があります。これに伴い、静注（IV）液ソリューションは必要不可欠な栄養素や薬剤の正確な送達を容易にし、患者の迅速な回復を保証します。また、特に危機的な状況において、より迅速で統制のとれた治療が可能になります。

老年人口の増加

老年人口の増加が静注（IV）液市場の成長に大きく寄与しています。高齢化社会は様々な健康問題や慢性疾患にかかりやすく、点滴療法を含む複雑な医療介入を必要とすることが多いため、市場の成長を後押ししています。さらに、免疫力の低下、臓器機能の低下、その他の加齢に伴う生理的変化によって、老年人口が感染症や疾病にかかりやすくなっていることも、市場の成長を促進しています。これに伴い、静注（IV）液は必要不可欠な水分補給、栄養補給、薬物投与に不可欠であり、治療が的を絞った効率的なものとなります。さらに、ナトリウム、カリウム、カルシウム、マグネシウムなどの電解質の不均衡を回復するために静脈注射液が広く利用されていることも、成長を促進する要因となっています。

急速な技術進歩

医療と静注（IV）液製造の技術的進歩が市場成長に寄与しています。これに伴い、新技術はより専門的な溶液の調合を可能にし、特定の患者のニーズに対応し、静脈内治療の効率性と安全性を高めています。さらに、医療従事者がより高い精度と制御性で治療を実施できるようにする静注（IV）液ポンプや送達システムにおける最近の技術革新は、市場成長にプラスの影響を与えています。さらに、合併症のリスクを低減し、患者の転帰を改善するための点滴療法のモニタリングと管理における技術的ブレークスルーが、もう一つの成長促進要因として作用しています。さらに、生体適合性、個別化された治療計画、人工知能（AI）などの技術を統合してケアを強化することに焦点を当てた広範な研究開発（R&D）の取り組みが、市場の成長を支えています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の静注（IV）液市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：タイプ別
  • 市場内訳：栄養別
  • 市場内訳：地域別
  • 市場予測
  • SWOT分析
    • 概要
    • 強み
    • 弱み
    • 機会
    • 脅威
  • バリューチェーン分析
    • 概要
    • 研究開発
    • 原料調達
    • 製造
    • マーケティング
    • 流通
    • 最終用途
  • ポーターのファイブフォース分析
    • 概要
    • 買い手の交渉力
    • 供給企業の交渉力
    • 競合の程度
    • 新規参入業者の脅威
    • 代替品の脅威

第6章 市場内訳：タイプ別

  • 部分非経口栄養
    • 市場動向
    • 市場予測
  • 総合非経口栄養剤
    • 市場動向
    • 市場予測

第7章 市場内訳：栄養別

  • 炭水化物
    • 市場動向
    • 市場予測
  • 塩分・電解質
    • 市場動向
    • 市場予測
  • ミネラル
    • 市場動向
    • 市場予測
  • ビタミン
    • 市場動向
    • 市場予測
  • アミノ酸
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • アジア太平洋
    • 市場動向
    • 市場予測
  • 中東・アフリカ
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第9章 点滴液の製造工程

  • 製品概要
  • 原材料要件
  • 製造プロセス
  • 主な成功要因とリスク要因

第10章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Ajinomoto
    • B. Braun Melsungen
    • Baxter International Inc.
    • Grifols
    • Otsuka Pharmaceutical
図表

List of Figures

  • Figure 1: Global: Intravenous Solutions Market: Major Drivers and Challenges
  • Figure 2: Global: Intravenous Solutions Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Intravenous Solutions Market: Breakup by Type (in %), 2023
  • Figure 4: Global: Intravenous Solutions Market: Breakup by Nutrients (in %), 2023
  • Figure 5: Global: Intravenous Solutions Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Intravenous Solutions Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Intravenous Solutions Industry: SWOT Analysis
  • Figure 8: Global: Intravenous Solutions Industry: Value Chain Analysis
  • Figure 9: Global: Intravenous Solutions Industry: Porter's Five Forces Analysis
  • Figure 10: Global: Intravenous Solutions (Partial Parenteral Nutrition) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Intravenous Solutions (Partial Parenteral Nutrition) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Intravenous Solutions (Total Parenteral Nutrition) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Intravenous Solutions (Total Parenteral Nutrition) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Intravenous Solutions (Carbohydrates) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Intravenous Solutions (Carbohydrates) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Intravenous Solutions (Salts and Electrolytes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Intravenous Solutions (Salts and Electrolytes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Intravenous Solutions (Minerals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Intravenous Solutions (Minerals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Intravenous Solutions (Vitamins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Intravenous Solutions (Vitamins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Intravenous Solutions (Amino Acids) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Intravenous Solutions (Amino Acids) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: Intravenous Solutions Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: Intravenous Solutions Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Europe: Intravenous Solutions Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Europe: Intravenous Solutions Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Asia Pacific: Intravenous Solutions Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Asia Pacific: Intravenous Solutions Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Middle East and Africa: Intravenous Solutions Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Middle East and Africa: Intravenous Solutions Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Latin America: Intravenous Solutions Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Latin America: Intravenous Solutions Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Intravenous Solutions Manufacturing: Detailed Process Flow

List of Tables

  • Table 1: Global: Intravenous Solutions Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Intravenous Solutions Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Intravenous Solutions Market Forecast: Breakup by Nutrients (in Million US$), 2024-2032
  • Table 4: Global: Intravenous Solutions Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Intravenous Solutions: Raw Material Requirements
  • Table 6: Global: Intravenous Solutions Market: Competitive Structure
  • Table 7: Global: Intravenous Solutions Market: Key Players
目次
Product Code: SR112024A891

The global intravenous solutions market size reached US$ 14.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 23.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032. The increasing prevalence of chronic diseases, rising geriatric population, rapid technological advancements, increasing expansion of healthcare facilities, imposition of supportive policies by governments and regulatory bodies, and rising shift towards home healthcare are some of the major factors propelling the market.

Intravenous (IV) solutions refer to sterile liquids used to administer fluids directly into a patient's bloodstream. It includes isotonic, hypertonic, and hypotonic solutions, catering to different medical needs. They are produced using various ingredients, such as water, electrolytes, sugars, vitamins, and medications. IV solutions are widely used in hydration therapy, nutritional support, medication delivery, blood transfusion, chemotherapy, pain management, correcting electrolyte imbalances, and detoxification treatments. They offer several benefits, such as controlled administration, reduced digestive system impact, tailored nutrient delivery, direct bloodstream access, and enhanced recovery support.

The rapid expansion of healthcare facilities, such as hospitals, clinics, and specialized care centers, which are generating more opportunities for IV treatments, is propelling the market growth. Additionally, the imposition of supportive policies by governments and regulatory bodies to ensure the availability of high-quality intravenous solutions across healthcare facilities is positively influencing the market growth. Furthermore, the growing demand for IV solutions in emergency scenarios and surgical procedures is contributing to the market growth. Apart from this, the increasing shift towards home healthcare, where patients receive treatment in their own homes, is facilitating the demand for specialized IV solutions. Besides this, the rising product application in treating a large number of patients quickly during global health emergencies, such as pandemics, is catalyzing the market growth.

Intravenous Solutions Market Trends/Drivers:

The increasing prevalence of disease

The heightened prevalence of chronic diseases, such as diabetes, cardiovascular ailments, cancer, and acute conditions, which necessitate IV treatments, is a prominent factor propelling the market growth. Furthermore, emerging global trends, such as lifestyle changes, environmental factors, and genetic predispositions, which lead to an increase in chronic conditions, are acting as another growth-inducing factor. Additionally, several chronic and acute illnesses require direct administration of fluids, nutrients, or medications into the bloodstream. In line with this, IV solutions facilitate precise delivery of essential nutrients and medication and ensure quick patient recovery. In addition, they also enable faster, more controlled care, particularly in critical situations.

The rising geriatric population

The rising geriatric population is contributing significantly to the growth of the IV solutions market. The high susceptibility of the aging population to various health issues and chronic conditions, which often require complex medical interventions, including IV therapy, is propelling the market growth. Furthermore, the presence of a weaker immune system, reduced organ functionality, and other age-related physiological changes that make geriatric individuals more prone to infections and diseases are facilitating the market growth. In line with this, IV solutions are vital in providing essential hydration, nutrients, and medications, ensuring that the treatments are targeted and efficient. Moreover, the widespread utilization of IV solutions to restore imbalance in electrolytes, such as sodium, potassium, calcium, and magnesium, is acting as another growth-inducing factor.

The rapid technological advancements

Technological advancements in medical care and the production of IV solutions are contributing to the market growth. In line with this, new technologies are enabling the formulation of more specialized solutions, catering to specific patient needs, and enhancing the efficiency and safety of IV therapies. Furthermore, the recent innovations in infusion pumps and delivery systems, which allow healthcare providers to administer treatments with greater precision and control, are positively influencing the market growth. Additionally, technological breakthroughs in monitoring and managing IV therapies to lower the risk of complications and improve patient outcomes are acting as another growth-inducing factor. Moreover, extensive research and development (R&D) efforts focusing on biocompatibility, personalized treatment plans, and integrating technology, such as artificial intelligence (AI), to augment care are supporting the market growth.

Intravenous Solutions Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global intravenous solutions market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on type and nutrients.

Breakup by Type:

Partial Parenteral Nutrition

Total Parenteral Nutrition

Total parenteral nutrition dominates the market

The report has provided a detailed breakup and analysis of the market based on type. This includes partial parenteral nutrition and total parenteral nutrition. According to the report, total parenteral nutrition represented the largest segment.

Total parenteral nutrition (TPN) is dominating the market as it is used to fulfill all the nutritional requirements of patients who cannot eat or absorb enough food through regular digestive means. Additionally, it finds extensive applications across various medical fields, including oncology, gastroenterology, and intensive care units (ICUs). Furthermore, the rising number of chronic conditions, such as cancer and gastrointestinal diseases, that necessitate the use of TPN for nutritional support is propelling the market growth. Apart from this, increasing utilization of TPN to meet the nutritional needs of patients undergoing major surgical procedures is catalyzing the market growth. Moreover, the recent improvements in TPN formulation and administration technology, ensuring safer and more personalized nutrition support, are strengthening the market growth.

Breakup by Nutrients:

Carbohydrates

Salts and Electrolytes

Minerals

Vitamins

Amino Acids

A detailed breakup and analysis of the market based on the nutrients has also been provided in the report. This includes carbohydrates, salts and electrolytes, minerals, vitamins, and amino acids.

Carbohydrates serve as a primary energy source for the human body. They are essential in providing immediate energy, particularly for patients unable to consume food orally. In addition, they are used by all cells in the body, which makes them suitable for a diverse range of patients, irrespective of their specific conditions. Furthermore, carbohydrates can be easily administered through IV solutions, allowing for controlled delivery.

Minerals, such as magnesium, calcium, potassium, and sodium, play critical roles in maintaining various bodily functions, including muscle contraction, nerve transmission, and maintaining fluid balance. Furthermore, IV solutions with specific mineral compositions are essential in correcting electrolyte imbalance, restoring normal cellular function, and stabilizing the patient. Apart from this, minerals are utilized in various medical scenarios, from emergency care to post-operative recovery and chronic disease management.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America exhibits a clear dominance, accounting for the largest intravenous solutions market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

North America hosts one of the world's most advanced healthcare systems comprising state-of-the-art medical facilities equipped with cutting-edge technology that is fostering a conducive environment for the utilization of IV solutions. Additionally, the region's healthcare spending is among the highest globally, enabling greater access to quality medical care, including treatments requiring intravenous solutions. Furthermore, the implementation of a comprehensive regulatory framework by the regional governments to ensure that IV solutions meet strict quality and safety standards is boosting the market growth. Apart from this, the high prevalence of chronic conditions like diabetes, heart disease, and cancer, which necessitates regular medical interventions, is acting as another growth-inducing factor. Besides this, North America has a strong network of universities, research institutions, and pharmaceutical companies that are actively investing in developing new intravenous solutions and improving existing ones.

Competitive Landscape:

The major players are focusing on creating advanced intravenous products, such as the formulation of new solutions with improved efficiency, the integration of innovative technologies like smart infusion pumps, and the development of personalized therapies. In addition, they are expanding their reach into these regions by setting up new manufacturing facilities, partnering with local distributors, and adapting products to meet specific regional needs. Furthermore, leading companies are engaging in mergers and acquisitions to diversify their product portfolios, leverage synergies, and expand their geographical presence. Moreover, they are placing strong emphasis on quality control and regulatory compliance to ensure that their products meet all relevant safety and efficacy standards. Besides this, top companies in the IV solutions market are focusing on environmentally responsible manufacturing processes and materials by reducing waste and energy consumption and using sustainable resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Ajinomoto Co., Inc.

B. Braun Melsungen AG

Baxter International, Inc.

Grifols S.A.

Otsuka Pharmaceutical.

Recent Developments:

In February 2022, B. Braun Medical has obtained approval from the U.S. Food and Drug Administration to commence activities at its recently established manufacturing facility for IV saline solutions located in Daytona Beach, Florida.

In July 2021, Grifols S.A. announced the establishment of an intravenous (IV) solutions production plant in Nigeria.

In March 2022, Otsuka Pharmaceutical. received regulatory approval in Japan for the sale of SAMTASU intravenous infusion for treating cardiac edema.

Key Questions Answered in This Report

  • 1. What is the expected growth rate of the global intravenous solutions market during 2024-2032?
  • 2. What are the key factors driving the global intravenous solutions market?
  • 3. What has been the impact of COVID-19 on the global intravenous solutions market?
  • 4. What is the breakup of the global intravenous solutions market based on the type?
  • 5. What is the breakup of the global intravenous solutions market based on the nutrients?
  • 6. What are the key regions in the global intravenous solutions market?
  • 7. Who are the key players/companies in the global intravenous solutions market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Intravenous Solutions Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Type
  • 5.5 Market Breakup by Nutrients
  • 5.6 Market Breakup by Region
  • 5.7 Market Forecast
  • 5.8 SWOT Analysis
    • 5.8.1 Overview
    • 5.8.2 Strengths
    • 5.8.3 Weaknesses
    • 5.8.4 Opportunities
    • 5.8.5 Threats
  • 5.9 Value Chain Analysis
    • 5.9.1 Overview
    • 5.9.2 Research and Development
    • 5.9.3 Raw Material Procurement
    • 5.9.4 Manufacturing
    • 5.9.5 Marketing
    • 5.9.6 Distribution
    • 5.9.7 End-Use
  • 5.10 Porters Five Forces Analysis
    • 5.10.1 Overview
    • 5.10.2 Bargaining Power of Buyers
    • 5.10.3 Bargaining Power of Suppliers
    • 5.10.4 Degree of Competition
    • 5.10.5 Threat of New Entrants
    • 5.10.6 Threat of Substitutes

6 Market Breakup by Type

  • 6.1 Partial Parenteral Nutrition
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Total Parenteral Nutrition
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Nutrients

  • 7.1 Carbohydrates
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Salts and Electrolytes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Minerals
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Vitamins
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Amino Acids
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Intravenous Solutions Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Ajinomoto
      • 10.3.1.1 Company Overview
      • 10.3.1.2 Description
      • 10.3.1.3 Product Portfolio
      • 10.3.1.4 Financials
      • 10.3.1.5 SWOT Analysis
    • 10.3.2 B. Braun Melsungen
      • 10.3.2.1 Company Overview
      • 10.3.2.2 Description
      • 10.3.2.3 Product Portfolio
      • 10.3.2.4 Financials
      • 10.3.2.5 SWOT Analysis
    • 10.3.3 Baxter International Inc.
      • 10.3.3.1 Company Overview
      • 10.3.3.2 Description
      • 10.3.3.3 Product Portfolio
      • 10.3.3.4 Financials
      • 10.3.3.5 SWOT Analysis
    • 10.3.4 Grifols
      • 10.3.4.1 Company Overview
      • 10.3.4.2 Description
      • 10.3.4.3 Product Portfolio
      • 10.3.4.4 Financials
      • 10.3.4.5 SWOT Analysis
    • 10.3.5 Otsuka Pharmaceutical
      • 10.3.5.1 Company Overview
      • 10.3.5.2 Description
      • 10.3.5.3 Product Portfolio